Alcon Patanase chemistry issues
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alcon is testing a modified formulation of its pending olopatadine nasal spray Patanase after receiving "correspondence from…FDA requiring that the current formulation of the drug be modified to reduce or remove one of the inactive ingredients it contains before Patanase nasal spray can be approved," Alcon says Nov. 7. The company previously had indicated it expected such a request. The Patanase NDA for seasonal allergic rhinitis was submitted in December 2004; Patanase contains the same active ingredient as the firm's allergic conjunctivitis treatment Patanol...
You may also be interested in...
Alcon refiles NDA for Patanase
After pulling its Patanase (olopatadine) nasal spray NDA in November 2005, Alcon resubmits the application with an amendment to modify its formulation. The amendment includes six-month data from an agreed-upon study requested by FDA to remove or reduce one of the inactive ingredients (1Pharmaceutical Approvals Monthly November 2005, In Brief). The pending NDA seeks approval of the ophthalmic solution, which has the same active ingredient as the firm's Patanol ophthalmic solution, for treatment of allergic rhinitis...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.